| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations MT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ... Nature 492 (7427), 108-112, 2012 | 1891 | 2012 |
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013 | 905 | 2013 |
| Natural mutagenesis of human genomes by endogenous retrotransposons RC Iskow, MT McCabe, RE Mills, S Torene, WS Pittard, AF Neuwald, ... Cell 141 (7), 1253-1261, 2010 | 672 | 2010 |
| Reductive carboxylation supports redox homeostasis during anchorage-independent growth L Jiang, AA Shestov, P Swain, C Yang, SJ Parker, QA Wang, LS Terada, ... Nature 532 (7598), 255-258, 2016 | 572 | 2016 |
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) MT McCabe, AP Graves, G Ganji, E Diaz, WS Halsey, Y Jiang, ... Proceedings of the National Academy of Sciences 109 (8), 2989-2994, 2012 | 537 | 2012 |
| A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ... Cancer cell 28 (1), 57-69, 2015 | 488 | 2015 |
| An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer ML Burr, CE Sparbier, KL Chan, YC Chan, A Kersbergen, EYN Lam, ... Cancer cell 36 (4), 385-401. e8, 2019 | 423 | 2019 |
| Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 SK Verma, X Tian, LV LaFrance, C Duquenne, DP Suarez, KA Newlander, ... ACS medicinal chemistry letters 3 (12), 1091-1096, 2012 | 405 | 2012 |
| Cancer DNA methylation: molecular mechanisms and clinical implications MT McCabe, JC Brandes, PM Vertino Clinical Cancer Research 15 (12), 3927-3937, 2009 | 366 | 2009 |
| The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors D Zingg, J Debbache, SM Schaefer, E Tuncer, SC Frommel, P Cheng, ... Nature communications 6 (1), 6051, 2015 | 335 | 2015 |
| The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis DA Frohlich, MT McCabe, RS Arnold, ML Day Oncogene 27 (31), 4353-4362, 2008 | 242 | 2008 |
| Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss A Fedoriw, SR Rajapurkar, S O'Brien, SV Gerhart, LH Mitchell, ND Adams, ... Cancer cell 36 (1), 100-114. e25, 2019 | 232 | 2019 |
| BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models A Wyce, G Ganji, KN Smitheman, C Chung, S Korenchuk, Y Bai, ... PloS one 8 (8), e72967, 2013 | 224 | 2013 |
| Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway MT McCabe, JN Davis, ML Day Cancer research 65 (9), 3624-3632, 2005 | 211 | 2005 |
| Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 LD Ler, S Ghosh, X Chai, AA Thike, HL Heng, EY Siew, S Dey, LK Koh, ... Science translational medicine 9 (378), eaai8312, 2017 | 209 | 2017 |
| New IDH1 mutant inhibitors for treatment of acute myeloid leukemia UC Okoye-Okafor, B Bartholdy, J Cartier, EN Gao, B Pietrak, AR Rendina, ... Nature chemical biology 11 (11), 878-886, 2015 | 189 | 2015 |
| Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing SV Gerhart, WA Kellner, C Thompson, MB Pappalardi, XP Zhang, ... Scientific reports 8 (1), 9711, 2018 | 166 | 2018 |
| Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer MT McCabe, JA Low, S Daignault, MJ Imperiale, KJ Wojno, ML Day Cancer research 66 (1), 385-392, 2006 | 148 | 2006 |
| Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors TA Yap, JN Winter, L Giulino-Roth, J Longley, J Lopez, JM Michot, ... Clinical Cancer Research 25 (24), 7331-7339, 2019 | 126 | 2019 |
| Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia MB Pappalardi, K Keenan, M Cockerill, WA Kellner, A Stowell, C Sherk, ... Nature cancer 2 (10), 1002-1017, 2021 | 118 | 2021 |
